Molecular Effects of Topical Calcipotriene on Morphea

Status Terminated

Clinical Trial Summary

This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02411643
Study type	Interventional
Source	Northwestern University
Contact
Status	Terminated
Phase	Early Phase 1
Start date	March 2015
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03351114` - Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea	Phase 2
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Withdrawn	`NCT00230373` - Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study	Phase 3
Completed	`NCT01799174` - Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea	N/A
Recruiting	`NCT01808937` - Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Enrolling by invitation	`NCT04922736` - Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases	N/A
Withdrawn	`NCT04656704` - Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease	Early Phase 1
Completed	`NCT04752397` - The Influence of Extracorporeal Photopheresis on Skin Sclerosis
Terminated	`NCT03740724` - A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)	Phase 1/Phase 2
Completed	`NCT02222038` - Genetic Variants in Linear Localized Scleroderma	N/A